Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2547049 | 0.89 | — | — | |
| SCHEMBL4866927 | 0.82 | NPSR1 (0.35) | NPSR1LMNA | |
| SCHEMBL1971946 | 0.81 | NPSR1 (0.42) | NPSR1LMNA | |
| SCHEMBL4864227 | 0.81 | NPSR1 (0.47) | NPSR1LMNA | |
| SCHEMBL2305290 | 0.79 | NPSR1 (0.45) | NPSR1LMNA | |
| SCHEMBL4872719 | 0.79 | NPSR1 (0.45) | NPSR1LMNA | |
| SCHEMBL5113321 | 0.76 | CYP3A4 (0.40) | NPSR1LMNA | |
| SCHEMBL4863377 | 0.74 | NPSR1 (0.33) | NPSR1LMNA | |
| SCHEMBL4863381 | 0.74 | NPSR1 (0.33) | NPSR1LMNA | |
| SCHEMBL15564880 | 0.74 | FFAR3 (0.40) | NPSR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102383-A1 | LPAR1 Inhibitors | ABBVIE INC (US) | 2026-04-16 | — | — | US | disclosed |
| WO-2025226510-A1 | LPAR1 INHIBITORS | ABBVIE INC. (US) | 2025-10-30 | — | — | WO | disclosed |
| EP-4640274-A1 | LPAR1 INHIBITORS | AbbVie Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260102383-A1 | LPAR1 Inhibitors | LPAR1, LPAR6, LPAR2 | NPSR1 98/4885LMNA 728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.